To a lesser extent, PPARα agonists, especially fenofibrate and bezafibrate, also exhibit pleiotropic beneficial effects in dyslipidemia, CVD, NAFLD, and PBC. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.